Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eribulin + mifepristone
- Development stage
- Unknown
- Lead developer
- Corcept Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of eribulin, a microtubule inhibitor, and mifepristone, a glucocorticoid receptor (GR) antagonist. This novel combination is designed to improve antitumor activity in metastatic triple-negative breast cancer (TNBC) and other advanced solid tumors. Eribulin inhibits the growth phase of microtubules and sequesters tubulin into nonproductive aggregates, leading to G2/M cell-cycle block, disruption of mitotic spindles, and ultimately apoptotic cell death. Mifepristone acts as an antagonist of the glucocorticoid receptor, potentially enhancing the antitumor effects of eribulin.
- Brand names
- MifegymisoKorlymHalaven
- Other names
- mifepristone + eribulin mesylate
02
Targets
GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))PR (Progesterone receptor)
Beyond the preview
Go deeper on eribulin + mifepristone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eribulin + mifepristone.